An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone on a forum asked whether you need to test IGF (insulin-like growth factor) levels before starting a growth hormone (GH) secretagogue — a drug that stimulates your body to release more growth hormone. The short answer is: doctors often check IGF-1 levels before and during treatment, but whether it’s “necessary” depends on the drug, your health history, and the reason you’re taking it. This isn’t an absolute yes-or-no; it’s a safety and monitoring decision. IGF-1 is a hormone your liver makes when it responds to growth hormone. Think of growth hormone as the message and IGF-1 as one of the main action molecules that actually affects tissues. IGF-1 is easier to measure reliably in a blood test than intermittent pulses of growth hormone. A GH secretagogue (like some prescription drugs or research peptides) doesn’t dump massive synthetic GH into your body; instead it nudges your pituitary gland to release your own GH. That makes measuring IGF-1 useful because it shows whether the nudge is changing your overall growth-hormone activity. What the medical guidance and small studies show is mainly about monitoring and safety. Measuring IGF-1 before you start gives a baseline so a clinician knows if you already have high or low levels for your age. During treatment, repeated IGF-1 tests show whether the secretagogue is raising levels into a normal range, or pushing them too high. The evidence comes mostly from clinical practice and some trials of approved GH-related drugs; for many experimental secretagogues the data are limited. Effects vary: some people show modest rises within the normal range, others may have bigger increases. There’s no guaranteed effect for everyone. Why this matters to a regular person: IGF-1 influences tissue growth and metabolism. If your IGF-1 is already high, giving something that raises GH could push it further and raise risks. If it’s low, treatment might correct that. Knowing your levels helps a clinician tailor dose and decide whether treatment is appropriate. It’s especially relevant if you have health conditions that could be affected by higher growth signals, such as a history of certain cancers, active diabetes, or heart disease. Caveats and risks: IGF-1 is one piece of the puzzle. A single test can be affected by age, time of day, nutrition, and lab differences. Secretagogues are not all the same — some are approved medicines with known safety profiles, while others are experimental peptides with little long-term data. Potential side effects include joint pain, fluid retention, blood sugar changes, and theoretical risk of stimulating growth in existing tumors. People who are pregnant, have active cancer, or uncontrolled diabetes should avoid these agents unless a specialist advises otherwise. Finally, regulatory status matters: some products sold online are not approved and may be unsafe. Bottom line: testing IGF-1 before and during a GH secretagogue is a common, sensible safety step because it shows how your body is responding. Whether it’s strictly “necessary” depends on your personal risk factors and the specific agent — discuss testing and monitoring with a knowledgeable clinician before starting anything.
Source: r/Peptides